BCL2 and B-cell chronic lymphocytic leukemia: As Mcl-1 is a marker of resistance to Bcl-2 inhibitor, Venetoclax, this link highlights a new angle to target Mcl-1 and enhance the efficacy of Venetoclax which is exhibiting impressive single-agent activity (ORR 79%) in CLL, a malignancy highly dependent on Bcl-265 but only exhibited modest single-agent activity in AML (ORR 19%)86.